Financial News
Articles published by AstraZeneca
![](https://mms.businesswire.com/media/20230111005595/en/484259/5/Logo.jpg)
AIRSUPRA™ (PT027) approved in the US for asthma
January 11, 2023
From AstraZeneca
Via Business Wire
Tickers
AZN
![](https://mms.businesswire.com/media/20221213005788/en/484259/5/Logo.jpg)
![](https://mms.businesswire.com/media/20221208005337/en/484259/5/Logo.jpg)
![](https://mms.businesswire.com/media/20221208005335/en/484259/5/Logo.jpg)
![](https://mms.businesswire.com/media/20221207005239/en/484259/5/Logo.jpg)
![](https://mms.businesswire.com/media/20221130005401/en/484259/5/Logo.jpg)
AstraZeneca Showcases Strength of Hematology Portfolio and Pipeline Across Multiple Hard-to-Treat Conditions at ASH 2022
November 30, 2022
From AstraZeneca
Via Business Wire
Tickers
AZN
![](https://mms.businesswire.com/media/20221121005994/en/484259/5/Logo.jpg)
AstraZeneca Aims to Redefine Breast Cancer Care With New Data Across the Treatment Spectrum At SABCS 2022
November 22, 2022
From AstraZeneca
Via Business Wire
Tickers
AZN
![](https://mms.businesswire.com/media/20221111005248/en/484259/5/Logo.jpg)
IMFINZI and IMJUDO with chemotherapy approved in the US for patients with metastatic non-small cell lung cancer
November 11, 2022
From AstraZeneca
Via Business Wire
Tickers
AZN
![](https://mms.businesswire.com/media/20221110005849/en/484259/5/Logo.jpg)
AstraZeneca EVUSHELD Named on TIME’s List of the Best Inventions of 2022
November 10, 2022
From AstraZeneca
Via Business Wire
Tickers
AZN
![](https://mms.businesswire.com/media/20221109005402/en/484259/5/Logo.jpg)
![](https://mms.businesswire.com/media/20221026005413/en/484259/5/Logo.jpg)
![](https://mms.businesswire.com/media/20221026005411/en/484259/5/Logo.jpg)
![](https://mms.businesswire.com/media/20221024005329/en/484259/5/Logo.jpg)
![](https://mms.businesswire.com/media/20221020005093/en/484259/5/Logo.jpg)
![](https://mms.businesswire.com/media/20220915005056/en/1570884/4/DSC09624-RT-JW-R1.jpg)
![](https://mms.businesswire.com/media/20220912005737/en/484259/5/Logo.jpg)
![](https://mms.businesswire.com/media/20220911005051/en/484259/5/Logo.jpg)
![](https://mms.businesswire.com/media/20220911005050/en/484259/5/Logo.jpg)
![](https://mms.businesswire.com/media/20220911005049/en/484259/5/Logo.jpg)
![](https://mms.businesswire.com/media/20220909005080/en/484259/5/Logo.jpg)
![](https://mms.businesswire.com/media/20220905005055/en/1561005/5/IMFINZI-BTCs_Product_-_Packaging_Photo.jpg)
![](https://mms.businesswire.com/media/20220826005409/en/484259/5/Logo.jpg)
New data show FARXIGA significantly lowers the risk of cardiovascular death in patients with heart failure
August 27, 2022
From AstraZeneca
Via Business Wire
Tickers
AZN
![](https://mms.businesswire.com/media/20220826005408/en/484259/5/Logo.jpg)
![](https://mms.businesswire.com/media/20220824005212/en/484259/5/Logo.jpg)
AstraZeneca aims to transform cancer outcomes with new data across industry-leading portfolio at ESMO 2022
August 24, 2022
From AstraZeneca
Via Business Wire
Tickers
AZN
![](https://mms.businesswire.com/media/20220816005291/en/484259/5/Logo.jpg)
![](https://mms.businesswire.com/media/20220812005157/en/484259/5/Logo.jpg)
![](https://mms.businesswire.com/media/20220805005483/en/484259/5/Logo.jpg)
![](https://mms.businesswire.com/media/20220805005482/en/484259/5/Logo.jpg)
![](https://mms.businesswire.com/media/20220805005419/en/484259/5/Logo.jpg)
CALQUENCE® (acalabrutinib) tablet formulation approved in the US across current indications
August 05, 2022
From AstraZeneca
Via Business Wire
Tickers
AZN
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.